Research Topics
Species | Albert LaiSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Oculodentodigital dysplasia connexin43 mutations result in non-functional connexin hemichannels and gap junctions in C6 glioma cellsAlbert Lai
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
J Cell Sci 119:532-41. 2006....- Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiformeAlbert Lai
David Geffen School of Medicine at UCLA, Reed Neurological Research Center, Los Angeles, CA 90095, USA
J Clin Oncol 29:142-8. 2011..The objectives were to determine the efficacy of this treatment combination and the associated toxicity... - Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerabilityAlbert Lai
Department of Neurology, David Geffen School of Medicine at University of California Los Angeles, 710 Westwood Plaza, Los Angeles, CA 90095, USA
Int J Radiat Oncol Biol Phys 71:1372-80. 2008.... - Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumabBenjamin M Ellingson
Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, 924 Westwood Blvd, Suite 650, Los Angeles, CA 90095, USA
J Neurooncol 106:111-9. 2012..5T) following anti-VEGF treatment (Wilcoxon signed rank test, P < 0.0001). An elevated residual, post-treatment, median T2 was predictive of both progression-free (Log-rank, P = 0.0074) and overall survival (Log-rank, P = 0.0393)... - Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumabBenjamin M Ellingson
Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90024, USA
J Neurooncol 105:91-101. 2011..0001) as well as overall survival (OS; P = 0.0093). Similarly, the mean proliferation rate was able to stratify patients with early and late PFS as well as OS... - Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysisWhitney B Pope
Department of Radiological Sciences, David Geffen School of Medicine at University of California Los Angeles UCLA Medical Center, 10833 Le Conte Ave, BL 428 CHS, Los Angeles, CA 90095 1721, USA
Radiology 249:268-77. 2008..To determine the difference in gene expression between completely versus incompletely enhancing glioblastoma multiforme (GBM)... - Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspectiveFranziska Walter
Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA, USA
J Nucl Med 53:393-8. 2012..We investigated the impact of (18)F-DOPA brain PET/CT on the clinical management of patients with known or suspected brain tumors... - Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumabBenjamin M Ellingson
Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
Magn Reson Med 67:237-45. 2012..Results suggest that nonlinear registration of pretreatment ADC maps to post-treatment ADC maps improves the clinical predictability, sensitivity, and specificity of fDMs for both progression-free and overall survival... - Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomasBarbara J Fueger
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
J Nucl Med 51:1532-8. 2010..The aims of the current study were to determine whether the degree of (18)F-FDOPA uptake in brain tumors predicted tumor grade and was associated with tumor proliferative activity in newly diagnosed and recurrent gliomas... - Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumabBenjamin M Ellingson
Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, 924 Westwood Blvd, Suite 650, Los Angeles, CA 90024, USA
Neuro Oncol 13:1151-61. 2011..001). These results demonstrate that spatially resolved diffusion-based tumor metrics are a powerful imaging biomarker of survival in patients with recurrent GBM treated with bevacizumab... - Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumabBenjamin M Ellingson
Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
Neuro Oncol 13:401-9. 2011..Initial contrast-enhancing volume was predictive of PFS but not OS. The pretreatment relative nonenhancing tumor ratio, defined as the ratio of FLAIR to contrast-enhancing volume, was found to be predictive of both PFS and OS... - Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zoneMelanie Kappadakunnel
University of California Los Angeles, Los Angeles, CA 90095, USA
J Neurooncol 96:359-67. 2010..More research is required to clarify the relationship between the SVZ, cancer stem cells and survival... - High order diffusion tensor imaging in human glioblastomaBenjamin M Ellingson
Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095 1721, USA
Acad Radiol 18:947-54. 2011..The purpose of the current study was to examine higher order diffusion characteristics in human glioblastoma prior to surgical resection using the fourth-order diffusion tensor model... - The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivityMaya Remington
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Neuro Oncol 11:22-32. 2009..These findings may provide a clue to determining the clinical significance of MGMT coding-region polymorphisms... - Tyrosine-dependent basolateral targeting of human connexin43-eYFP in Madin-Darby canine kidney cells can be disrupted by the oculodentodigital dysplasia mutation L90VJana Chtchetinin
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
FEBS J 276:6992-7005. 2009..These findings raise the possibility that some oculodentodigitial dysplasia-associated mutations contribute to disease by altering polarized targeting of Cx43... - Safety of anticoagulation use and bevacizumab in patients with gliomaPhioanh Leia Nghiemphu
Department of Neurology, David Geffen School of Medicine at UCLA, 710 Westwood Plaza, RNRC 1 230, Los Angeles, CA 90095, USA
Neuro Oncol 10:355-60. 2008..In this retrospective review, anticoagulation did not lead to any major hemorrhages and does not appear to be a contraindication for starting bevacizumab therapy... - Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomasBenjamin M Ellingson
Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
Neuroimage 59:908-16. 2012.... - Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastomaBenjamin M Ellingson
Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA 90024, USA
Neuro Oncol 14:333-43. 2012..The current study supports the hypothesis that fDM is a sensitive imaging biomarker for predicting survival in glioblastoma... - Time course of imaging changes of GBM during extended bevacizumab treatmentSuchitra Ananthnarayan
Department of Radiology, David Geffen School of Medicine, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095 1721, USA
J Neurooncol 88:339-47. 2008.... - Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot studyWei Chen
Ahmanson Biological Imaging Division and the Department of Molecular and Medical Pharmacology, Biostatistics, Radiology, University of California, Los Angeles, Los Angeles, CA 90005 6942, USA
J Clin Oncol 25:4714-21. 2007.... - Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatmentWhitney B Pope
Department of Radiological Sciences, David Geffen School of Medicine at UCLA Medical Center, 10833 Le Conte Ave, BL 428 CHS, Los Angeles, CA 90095 1721, USA
Radiology 252:182-9. 2009..To determine if apparent diffusion coefficient (ADC) histogram analysis can stratify progression-free survival in patients with recurrent glioblastoma multiforme (GBM) prior to bevacizumab treatment... - Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 casesOrestes E Solis
Department of Pathology and Laboratory Medicine, Section of Neuropathology, University of California, Los Angeles, Los Angeles, CA, USA
J Neurooncol 102:477-84. 2011..Reported outcome is nearly uniformly excellent after complete or subtotal resection. A solitary report of recurrence after 10 years and the limited experience with this entity suggest that long term follow up is advisable... - Genomic landscape of meningiomasYohan Lee
Department of Human Genetics, UCLA School of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, Calif 90095 7088, USA
Brain Pathol 20:751-62. 2010..These data offer the most complete description of the genomic landscape of meningiomas, and provide broad genomic information that may be used to further stratify meningioma patients into prognostic risk groups... - Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastomaTim F Cloughesy
Department of Neurology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
PLoS Med 5:e8. 2008..Small, molecularly focused clinical studies offer the promise of the early definition of optimal biologic dose and patient population... - Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2Marc R J Carlson
Department of Human Genetics, University of California at Los Angeles and David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California 90095 1271, USA
Clin Cancer Res 13:2592-8. 2007..VEGF inhibition reduces edema and tumor burden in some patients with malignant glioma, whereas others show no response. The role of VEGF expression in edema production and the relationship to survival is not well understood... - Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of OriginAlbert Lai
Genentech, 1 DNA Way, South San Francisco, CA 94080
J Clin Oncol 29:4482-90. 2011..Optimal clinical management should account for the distinction between these GBM disease subtypes... - Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopyWhitney B Pope
Department of Radiological Sciences, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, CA, 90095, USA
J Neurooncol 107:197-205. 2012..In addition to 2-HG, alterations in several other metabolites measured by MRS correlate with IDH1 mutation status... - In Silico Enhanced Restriction Enzyme Based Methylation Analysis of the Human Glioblastoma Genome Using Agilent 244K CpG Island MicroarraysAnh Tran
Department of Neurology, David Geffen School of Medicine at UCLA Los Angeles, CA, USA
Front Neurosci 3:57. 2009..These data provide general guidance to individuals seeking to maximize effective coverage using restriction enzyme based methylation profiling approaches...